Biotinoyl Tripeptide-1 (Topical) Dosage Protocol
The hair peptide inside Procapil, and the ingredient most often used at the wrong strength. The famous “3%” belongs to Procapil, not to the peptide — the only human trial ran at 6 parts per million of actual peptide. This page works from the manufacturer’s own dossier to the arithmetic, and states plainly what the evidence does and does not show. Research and educational reference only.
Biotin joined to the tripeptide GHK (glycyl-histidyl-lysyl), the same copper-binding fragment behind GHK-Cu. Manufacturer in-vitro work attributes its effect to hair-bulb keratinocyte proliferation and to collagen IV and laminin 5, the adhesion proteins that anchor the follicle in the dermis.
A formulation concentration, not a dose, and the number in circulation is for the wrong material. The Sederma dossier documents 2 ppm of peptide at 1% Procapil and a recommended 3% Procapil use level, which is 6 ppm - 0.0006% - of actual peptide in the finished product.
Topical only, on the scalp or lash line. Sold as a water-soluble white powder from about 0.1 g upward, and as a pre-diluted glycerin concentrate. Suppliers say to add it to the water phase below 40 degrees C.
No PubMed-indexed study of the peptide on its own. Every human trial tested Procapil, a three-active complex, and most tested that complex inside a larger product or alongside PRP or minoxidil. Not FDA-approved and not a minoxidil or finasteride substitute.
Quickstart Highlights
Biotinoyl Tripeptide-1 is a cosmetic peptide made by joining biotin to GHK (glycyl-histidyl-lysyl), the tripeptide that also sits at the centre of GHK-Cu. PubChem lists it as CID 11534242, molecular formula C24H38N8O6S, molecular weight 566.7 g/mol, CAS 299157-54-3[1]. The arithmetic is a good sanity check on the identity: GHK weighs 340.38, biotin weighs 244.31, and joining them releases a molecule of water — 340.38 + 244.31 − 18.02 = 566.67, which is exactly what suppliers list[9]. Vendors also call it biotinyl-GHK or biotin-GHK; it is the same molecule.
It is best known as the peptide inside Procapil, Sederma’s hair active. That is where nearly all the numbers attached to this ingredient come from, and it is also where they go wrong, because Procapil is not the peptide. Procapil is a solution of three actives — apigenin, oleanolic acid and biotinoyl tripeptide-1 — in a butylene glycol and water base[2]. The peptide is the last name on that INCI list, which in cosmetic labelling means the smallest amount, and the manufacturer’s own dossier says exactly how small. Getting that one relationship straight is what this page is for.
Supplies Needed
This is a cosmetic raw material, not a research vial, and nothing about it is reconstituted or injected. One supplier checked on 9 August 2026 sells it as a 99% whitish powder in pack sizes from 0.1 g to 50 g, describes it as water-soluble and instructs formulators to add it to the batch below 40 °C[9]. Another lists ≥98% purity as a white powder with the same formula and molecular weight[1]. A pre-diluted glycerin concentrate is also sold as an alternative to powder. What you need is a formulation to put it in, an accurate way to measure a very small mass, and a certificate of analysis showing CAS 299157-54-3.
Protocol Overview
The molecule is a well-known peptide with a vitamin bolted on. GHK is the copper-binding tripeptide isolated from human plasma and used across cosmetic chemistry, most familiar as GHK-Cu. Attaching biotin through an amide bond gives biotinoyl tripeptide-1, described by ingredient databases simply as “the reaction product of biotin and tripeptide-1”[10]. If you already know GHK-Cu, you know most of the parent chemistry here; what biotin adds is a lipophilic tail argued to improve affinity for the follicle.
Procapil is the reason anyone has heard of it, and Procapil is three actives, not one. Sederma’s dossier gives the INCI as butylene glycol, water, PPG-26-buteth-26, PEG-40 hydrogenated castor oil, apigenin, oleanolic acid and biotinoyl tripeptide-1[2]. The positioning of each is different: oleanolic acid is presented as acting on 5-alpha-reductase, apigenin on scalp microcirculation, and the peptide on follicle anchorage. Any result from a Procapil study belongs to that combination, and it cannot be assigned to the peptide.
The published human record is about the complex, and usually about the complex inside something else. PubMed returns six indexed articles for Procapil or biotinoyl tripeptide (checked 9 August 2026) and not one studies the peptide alone. Two combined Procapil with platelet-rich plasma[4][5], one paired it with caffeine[8], one tested a four-active serum in which Procapil was a component[6], one evaluated a branded serum as an add-on to minoxidil[7], and one is a review of the whole hyped-actives category[3].
Dosing Protocol
Reference conversions only. Each row starts from a concentration of peptide in the finished product, works out the mass a 100 g batch would need, and states what a single gram of powder covers. The first three rows are the manufacturer’s documented figures; the last two are what happens when a percentage written for a different material is applied to raw powder.
| Peptide in the finished product | Per 100 g batch | What 1 g of powder covers |
|---|---|---|
| 2 ppm (0.0002%) — ex vivo, growth +58% vs control[2] | 0.2 mg | ≈ 500 kg |
| 5 ppm (0.0005%) — ex vivo, growth +121% vs control[2] | 0.5 mg | ≈ 200 kg |
| 6 ppm (0.0006%) — the level in the 4-month human trial[2] | 0.6 mg | ≈ 167 kg |
| 10–50 ppm (0.001–0.005%) — raw-material supplier band[9] | 1–5 mg | ≈ 20–100 kg |
| 2,000 ppm (0.2%) — the same supplier’s “hair loss” figure[9] | 200 mg | ≈ 500 g |
| 30,000 ppm (3%) — the Procapil use level misapplied to powder | 3,000 mg | ≈ 33 g — 5,000× the trial level |
Why Biotinoyl Tripeptide-1 draws research interest
These are the directions researchers and the peptide community most often explore Biotinoyl Tripeptide-1 for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
The 3% that is not 3%
The famous use level is 3% of Procapil, which works out at six parts per million of the peptide itself.
A supplier that contradicts itself
The same raw-material page recommends 0.001-0.005% and then quotes 0.2% for hair loss — a fortyfold jump.
Never tested alone
Every published human study used Procapil, and most stacked it on PRP, minoxidil or a four-active serum.
It lost its one head-to-head
In the only indexed comparison, the redensyl-saw-palmetto-biotin arm came out ahead of the Procapil arm.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
The documented finished-product level is 6 ppm (0.0006%) of peptide, from 3% Procapil — not 3% of peptide[2].
At 6 ppm, a single gram of powder is enough for about 167 kg of finished product.
None. All six PubMed hits study Procapil, the three-active complex, and most study it inside a larger product[3].
Two, both eyelash serums with many ingredients (n = 19 and n = 35). Neither tests this peptide by itself[11].
Dosing & Application
Biotinoyl Tripeptide-1 is applied to the scalp or lash line inside a finished formulation. The only quantity with a documented basis is the concentration of peptide in that formulation, and this ingredient carries the widest gap between the quoted figure and the real one that we have seen on any cosmetic peptide. Four different percentages circulate for it, they describe four different materials, and they are separated by four orders of magnitude.
Standard / Gradual Approach
The manufacturer’s figure, and what it actually refers to. Sederma’s technical dossier for Procapil records that “2 ppm biotinyl-GHK” is the same thing as “1% PROCAPIL”, and that 5 ppm is 2.5% Procapil[2]. Both statements give the same answer: neat Procapil is about 200 ppm, or 0.02%, peptide. With a recommended use level of 3% Procapil, the finished product contains 6 ppm — 0.0006% — of biotinoyl tripeptide-1.
The raw-material supplier figures, which are higher and internally inconsistent. A cosmetic ingredient supplier selling the powder in 0.1 g to 50 g packs recommends 0.001–0.005% — 10 to 50 ppm, already up to eight times the Sederma level — and then adds on the same page that the “commonly used concentration for hair loss is at 0.2%”[9]. Two thousand parts per million is forty times its own top recommendation and more than three hundred times the concentration in the trial. When a supplier’s own sheet disagrees with itself by that margin, the number is marketing, not a specification.
The concentrate, which is a third material again. Some suppliers sell a pre-diluted glycerin concentrate at 5,000 ppm (0.5%) rather than powder. Using “2%” of that concentrate gives 100 ppm in the finished product. It is a perfectly reasonable presentation, and it is a third percentage attached to the same INCI name — which is precisely why a percentage is meaningless here unless the material it refers to is stated alongside it.
The practical consequence: at documented levels this cannot be weighed. A 100 g batch at 6 ppm needs 0.6 mg of powder, which no ordinary balance will read. The working method is a stock solution — dissolve 1 g in 100 mL of water to get 10 mg/mL, and 0.6 mg is then 60 µL, measurable with a pipette. Only at the supplier’s contested 0.2% figure does direct weighing become possible, and that is the figure with the least support behind it.
Storage Instructions
Store the powder cool, dry, dark and tightly closed, and follow the batch-specific guidance on the certificate of analysis. It is water-soluble, so keep it away from humidity as well as heat[9].
Add it late and cool. Supplier guidance is to incorporate it into the water phase below 40 °C[9]. That constraint comes from the material itself, not from a stability study of your particular formula.
A stock solution has its own shelf life. If you make one in order to measure milligram amounts, remember that an unpreserved aqueous peptide solution is a growth medium. It needs a preservative system and a date on the bottle, and once the peptide is in a finished product it is the product’s preservation, not the peptide’s, that governs.
Important Notes
These are the points that vanish once this ingredient reaches a marketing page.
- ▪The single most important correction on this page. “Use at 3%” is a Sederma instruction about Procapil, a solution containing roughly 200 ppm of peptide[2]. The peptide concentration that instruction produces is 6 ppm. A DIY formulation using 3% raw powder is not following the manufacturer — it is at five thousand times the only concentration ever tested on human volunteers.
- ▪The ex-vivo results are the source of the ppm figures, and they are manufacturer-commissioned. In cultured hair follicles, the dossier reports that 2 ppm biotinyl-GHK gave growth 58% greater than control, “in a similar manner to that in the presence of Minoxidil 2 ppm”, and 5 ppm gave 121% greater growth[2]. That is an explant model, run for the ingredient supplier, and it is not the same claim as matching minoxidil on a human scalp.
- ▪The human trial is small, and it tested the complex. Thirty-five subjects, 18 on Procapil and 17 on placebo, mean age around 37, randomised, twice-daily application of a 3% Procapil dilute alcohol lotion for four months at Laboratoires DERMSCAN. The dossier reports a significant increase in the anagen/telogen ratio and describes it as comparable to oral finasteride[2]. That comparison appears in a supplier document, not in a peer-reviewed head-to-head trial, and the product tested contained three actives.
- ▪The one indexed head-to-head did not favour Procapil. In a randomised study of 54 men, one arm received Procapil with platelet-rich plasma and the other redensyl, saw palmetto and biotin with PRP. The authors concluded that the redensyl arm “can be a better alternative to the current therapies of PRP”[5]. It is a small single-centre study, but it is the closest thing to an independent comparison that exists, and it went the other way.
- ▪A dermatology review names the problems in this whole category. Reviewing Procapil alongside Redensyl, Capixyl, Baicapil and the rest, the authors report that these actives have been studied “mostly as combined formulations” and that most studies suffer from limited sample size, no comparison with standard therapies, non-uniform study groups, non-disclosure of the type of alopecia treated, and conflicts of interest[3]. That is a fair description of the record for this ingredient specifically.
- ▪Industry involvement should be visible, not hidden. The 2025 observational study of a Procapil-containing serum as an add-on to minoxidil was conducted with two authors employed by the pharmaceutical company marketing the product[7]. That does not make the result wrong; it does mean it is not independent evidence.
- ▪The eyelash figures describe a diluted commercial form. The widely repeated “17% longer, 19% thicker after 30 days” comes from a manufacturer study of 30 volunteers using a mascara containing 2% of a commercial preparation of the peptide, not 2% of the peptide itself[10]. Same trap, different product.
How This Works
The proposed action is anchorage rather than stimulation. Sederma positions the peptide around the attachment of the follicle in the dermis, reporting increased proliferation markers and enhanced structuring by the adhesion proteins collagen IV and laminin 5[2]. Ingredient databases summarise the same in-vitro work as promoting hair-bulb keratinocyte proliferation and optimal hair anchorage[10].
The biotin is there as a delivery argument. The rationale for attaching biotin to GHK is that it makes the peptide more substantive to the follicle, and the dossier lists a dedicated substantiveness study on hair-follicle explants[2]. Whether biotin also acts as biotin at six parts per million on intact scalp is a separate question the studies do not address.
The other two Procapil actives carry most of the mechanistic story. Oleanolic acid is presented as acting on 5-alpha-reductase, the enzyme that produces DHT, and apigenin on scalp microcirculation. Neither is a peptide, and neither is what you are buying when you buy biotinoyl tripeptide-1 powder. Any Procapil result that depends on DHT or blood flow is not attributable to the peptide.
Lifestyle Factors
This is an adjunct at best, and the literature treats it that way. Every human study of the complex either added it to PRP, added it to minoxidil, or tested it inside a multi-active serum[4][5][6][7]. Nothing here is a replacement for minoxidil or finasteride, and androgenetic alopecia treated by a clinician is a different proposition from a formulation experiment.
Get the diagnosis before the ingredient. Hair loss has causes that a topical peptide does not touch — thyroid disease, iron deficiency, telogen effluvium after illness, traction, scarring alopecias. The dermatology review is explicit that many published studies did not even disclose which type of alopecia they were treating[3], which is exactly the mistake to avoid personally.
Judge results on a hair-cycle timescale. The one controlled study ran four months precisely because that covers a telogen cycle[2]. Anything assessed at four weeks is measuring shedding noise, and the vehicle — conditioning agents, glycols, alcohol — changes how hair looks and behaves long before any active could.
Potential Benefits & Side Effects
Evidence tier: manufacturer in-vitro and small clinical work on a three-active complex; nothing at all on the peptide alone. The reported effects below are listed with the material that was actually tested attached to each one, because that is the distinction the marketing removes. This is a cosmetic ingredient, it has no FDA approval, and none of the studies below tested biotinoyl tripeptide-1 by itself.
Reported Effects
- ▪Hair-follicle growth ex vivo — the peptide, at parts per million, in a supplier study: cultured follicles grew 58% more than control at 2 ppm biotinyl-GHK and 121% more at 5 ppm, with the 2 ppm result described as similar to minoxidil at the same concentration[2]. This is the only reported result attributed to the peptide on its own, and it is an explant model in a manufacturer dossier.
- ▪Anagen/telogen ratio — the complex, 35 subjects, four months: a placebo-controlled trial of a 3% Procapil lotion applied twice daily reported a significant increase in the anagen/telogen ratio, described in the dossier as comparable to oral finasteride[2]. Small, supplier-run, and testing three actives at once.
- ▪Added to platelet-rich plasma — the complex, 160 patients: a quasi-experimental trial found that PRP plus twice-daily topical 5% Procapil scored better on dermatologist evaluation and patient satisfaction at six months than PRP alone[4]. The comparison is PRP with versus without a topical, not the peptide versus placebo.
- ▪Head-to-head against another adjunct — the complex lost: in 54 men, Procapil with PRP was compared against redensyl, saw palmetto and biotin with PRP; the authors concluded the latter may be the better alternative[5].
- ▪Inside multi-active serums — positive but uncontrolled or industry-run: a four-active serum containing Procapil improved hair growth rate, thickness and density over 60 days in 32 subjects with no control group[6]; a Procapil-containing serum as an add-on to minoxidil reduced shedding in a 60-subject observational study co-authored by employees of the marketing company[7]. A caffeine-plus-3%-Procapil formulation was reported in a short journal letter[8].
- ▪Eyelashes — manufacturer data on a diluted preparation: 30 volunteers using a mascara with 2% of a commercial preparation of the peptide showed lashes 17% longer and 19% thicker after 30 days[10]. Manufacturer-conducted, and 2% of the preparation is far less than 2% of peptide.
Common Side Effects
- ▪The evidence problem here is attribution, not toxicity. Nothing in the record suggests this peptide is dangerous at cosmetic concentrations. What is missing is any study that isolates it, so every efficacy figure quoted for it belongs to a mixture[3].
- ▪It is not a minoxidil or finasteride substitute, and the studies never claimed to be testing one. They tested it as an addition to PRP or to minoxidil[4][7]. Replacing an evidence-backed treatment with a cosmetic ingredient is the most consequential mistake available with this molecule.
- ▪Irritation at the scalp is a vehicle problem more often than an active one. The trial lotion was alcohol-based[2], and alcohol, glycols, preservatives and pH do most of the irritating in hair products. Patch-test a new formulation on a small area before applying it across the scalp.
- ▪Over-concentrating has no upside and an obvious downside. The dose-response reported by the manufacturer runs from 2 to 5 ppm[2]; nothing above that band has been tested for efficacy or for skin tolerance. Formulating at hundreds or thousands of times the documented level buys no demonstrated benefit and puts an untested amount of an unstudied material on skin.
- ▪Not an approved drug for hair loss anywhere. It is a cosmetic ingredient regulated as such. Any product built around it is a cosmetic, and claims that it treats a medical condition are outside what the evidence and the regulatory category support.
How to Apply
There is nothing to reconstitute and nothing to inject. What follows is the workflow for turning a powder into a finished topical at a concentration that has some documented basis, and for judging the result honestly. It is educational reference, not a formulation service or medical advice.
Skin Preparation
- ▪Confirm the identity before anything else. The checks are CAS 299157-54-3, PubChem CID 11534242, formula C24H38N8O6S, MW 566.7[1]. Purity figures on the supplier sheets checked ranged from ≥98% to 99%[9]. Ask for the batch certificate rather than accepting the catalogue description.
- ▪Establish which material the percentage on the label refers to. Powder, a 5,000 ppm glycerin concentrate and Procapil itself are three different things with three different percentages. Write down which one you have before doing any arithmetic.
- ▪Decide the target concentration from the table, not from a forum. The documented band is 2–6 ppm of peptide in the finished product[2]. Everything else on this page follows from that number.
Applying the Product
- ▪Work out the mass, then decide whether you can weigh it. A 100 g batch at 6 ppm needs 0.6 mg. That is below what a normal balance resolves, so make a stock solution — 1 g in 100 mL of water gives 10 mg/mL, and 0.6 mg is 60 µL by pipette.
- ▪Add it to the water phase, late and cool. It is water-soluble and supplier guidance is to add it below 40 °C[9], which in practice means the cool-down stage rather than the heated phase.
- ▪Apply the way the trial did, if you want the trial to be relevant. The four-month study applied the lotion twice daily to the scalp with gentle massage[2]. A different frequency or a rinse-off product is a different experiment.
- ▪Do not compensate for a small number by making it a big one. Six parts per million looks like nothing on a scale, and that is exactly what the manufacturer’s own dose-response was built on. The concentration is small because the studies were.
After Application
- ▪Give it a hair cycle before judging it. The controlled study ran four months to cover one telogen phase[2]. Assessments before that are measuring normal shedding variation.
- ▪Attribute results honestly. If the formula also contains caffeine, redensyl, saw palmetto or minoxidil, the published record says those combinations work as combinations[4][5][6] — and gives you no way to credit the peptide specifically.
- ▪Keep the regulatory position straight. This is a cosmetic ingredient with no approval for treating hair loss, whose entire human evidence base is a three-active complex studied in small, mostly industry-linked trials[3]. Treat it as an optional addition to a hair routine, never as a treatment.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for Biotinoyl Tripeptide-1 (2-6 ppm).
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
PubChem CID 11534242 — Biotinoyl Tripeptide-1. National Center for Biotechnology Information.The chemical identity record: molecular formula C24H38N8O6S, molecular weight 566.7 g/mol, CAS 299157-54-3. The IUPAC name resolves the structure as biotin joined through a glycine to a histidine and a lysine — that is, biotin amide-linked to the GHK tripeptide. Retrieved 9 August 2026.
- 2
Sederma — PROCAPIL technical dossier: For enhanced anchorage of the hair, Matrikine and PhytoregulatorsThe originator’s own document and the primary source for every concentration on this page. It gives the INCI as butylene glycol, water, PPG-26-buteth-26, PEG-40 hydrogenated castor oil, apigenin, oleanolic acid and biotinoyl tripeptide-1; states that 2 ppm biotinyl-GHK is “i.e. 1% PROCAPIL” and 5 ppm is 2.5% PROCAPIL; gives the recommended dose for use as 3%; reports ex-vivo hair-follicle growth 58% above control at 2 ppm (similar to minoxidil at 2 ppm) and 121% above control at 5 ppm; and describes a four-month placebo-controlled trial at Laboratoires DERMSCAN in which a 3% Procapil dilute alcohol lotion was applied twice daily by 18 subjects against 17 on placebo, reporting a significant increase in the anagen/telogen ratio. A manufacturer dossier, not a peer-reviewed publication. Retrieved 9 August 2026.
- 3
International Journal of Trichology (2025) — Topical Alternatives for Hair Loss: Beyond the ConventionalBikash (PMID 40654553). A review of the most marketed topical hair actives, Procapil among them. Its conclusion is the honest frame for this entire page: these ingredients “have been studied mostly as combined formulations with other agents”, and most studies have limited sample size, lack comparison with standard therapies, are non-uniform between groups, do not disclose the type of alopecia treated, and carry conflicts of interest. DOI: 10.4103/ijt.ijt_8_23.
- 4
Journal of Ayub Medical College Abbottabad (2024) — Comparison of platelet rich therapy alone with platelet rich therapy along with daily topical 5% Procapil application for androgenetic alopeciaKhoso & Fahim (PMID 39609969). Quasi-experimental trial, 160 patients in two arms of 80. Group A received four PRP sessions four weeks apart; group B received the same PRP plus topical 5% Procapil twice daily. At six months, group B scored better on dermatologist evaluation and patient satisfaction. Tests Procapil, the three-active complex, as an addition to PRP — not the peptide, and not against placebo. DOI: 10.55519/JAMC-02-12749.
- 5
Cureus (2023) — A comparative study of topical Procapil with PRP versus topical redensyl, saw palmetto and biotin with PRP in androgenetic alopeciaPavithra et al. (PMID 37292551). Randomised controlled trial in 54 men, 27 per arm, four sessions at three-week intervals, assessed by a blinded observer on serial photography. The closest thing to an independent head-to-head this ingredient has, and the conclusion favoured the comparator: PRP with redensyl, saw palmetto and biotin “can be a better alternative to the current therapies of PRP”. DOI: 10.7759/cureus.38696.
- 6
Journal of Cosmetic Dermatology (2023) — Safety and efficacy of REGENDIL-infused hair growth promoting product in adults with hair fall complaintsMerja et al. (PMID 38050644). Thirty-two subjects applied 0.5 mL daily for 60 days of a serum containing REGENDIL (Redensyl, AnaGain, Procapil and Capilia longa) plus 5 kDa hyaluronic acid, with reported improvements in growth rate, thickness and density. Single-arm with no control group, and Procapil is one of five actives — illustrative of how deeply buried the peptide is in the evidence attributed to it. DOI: 10.1111/jocd.16084.
- 7
Journal of Cosmetic Dermatology (2025) — Real-world efficacy and safety of Cuticapil Stem Hair Serum as an add-on to minoxidil in androgenetic alopeciaDhurat et al. (PMID 40386829). Multicentre prospective observational study, 60 subjects, of a Procapil-containing serum added to standard care including minoxidil; reported significantly reduced shedding and better hair-pull and photographic scores than standard care alone. Two of the eleven authors are affiliated to Torrent Pharmaceuticals, the company marketing the product, which is disclosed in the affiliations and is worth knowing when weighing the result. DOI: 10.1111/jocd.70247.
- 8
Journal of Cosmetic Dermatology (2023) — Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair lossSamadi et al. (PMID 37990760). Published as a short letter without an indexed abstract, so the design and results cannot be checked from the record. Listed here for completeness because it is one of only six indexed papers naming Procapil, and because its title confirms the 3% figure is applied to Procapil rather than to the peptide. DOI: 10.1111/jocd.16102.
- 9
Cosmetic raw-material supplier listings for Biotinoyl Tripeptide-1 (Dermafactors; Bolise/bkherb), retrieved 9 August 2026.Independent supplier sheets establishing how the material is really sold and what formulators are told. Dermafactors lists pack sizes from 0.1 g to 50 g, 99% purity, “Whitish Powder”, water-soluble, “Add to the batch at a temperature <40 °C”, and states a recommended usage of “0.001-0.005%” while adding on the same page that the “commonly used concentration for hair loss is at 0.2%” — the internal contradiction discussed above. Bolise lists CAS 299157-54-3, C24H38N8O6S, MW 566.67, purity ≥98%, white powder, independently matching the PubChem record.
- 10
INCIDecoder — Biotinoyl Tripeptide-1 ingredient entryDescribes the molecule as “the reaction product of biotin and tripeptide-1”, identifies tripeptide-1 as GHK, and summarises the manufacturer in-vitro claims of hair-bulb keratinocyte proliferation and hair anchorage while noting they “might or might not translate to real-world use”. Source of the eyelash figures quoted on this page: a manufacturer study of 30 volunteers using a mascara with 2% of the commercial preparation, reporting lashes 17% longer and 19% thicker at 30 days. Retrieved 9 August 2026.
- 11
ClinicalTrials.gov — registered-study search for biotinoyl tripeptide-1 and Procapil as interventionsQueried 9 August 2026 through the ClinicalTrials.gov API: two registered studies surface, both eyelash serums containing many ingredients — a 19-subject prospective study of a prostaglandin-analogue-based lash serum and a 35-subject single-group study of a brand-sponsored lash serum. Neither is a trial of biotinoyl tripeptide-1 on its own, and neither is placebo-controlled for the peptide.
How to apply Biotinoyl Tripeptide-1
- 1Blend Biotinoyl Tripeptide-1 into a clean, water-based serum or cream base at the intended percentage (commonly 3 to 10 percent).
- 2Patch-test on a small area of skin first to check tolerability.
- 3Apply a thin layer to clean, dry skin as documented in cosmetic research (often once or twice daily).
- 4Store the raw powder and the finished serum sealed, cool and away from light; refrigerate water-based serums.
Biotinoyl Tripeptide-1 — frequently asked questions
How is Biotinoyl Tripeptide-1 used?
Biotinoyl Tripeptide-1 is a topical cosmetic peptide applied to the skin as part of a serum or cream — not injected or taken by mouth. It is blended into a water-based base at a chosen percentage and applied to clean skin.
What concentration of Biotinoyl Tripeptide-1 is typical?
Cosmetic formulations commonly use roughly 3 to 10 percent. Higher is not necessarily better and can affect texture, stability and skin tolerability. The strength shown on this page is a formulation reference, not a dose to inject.
Do I need bacteriostatic water or syringes for Biotinoyl Tripeptide-1?
No. As a topical peptide, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — it is dissolved into a serum or cream base and applied to the skin.
How should I store Biotinoyl Tripeptide-1?
Keep the raw powder sealed, cool, dry and away from light. A finished water-based peptide serum is best refrigerated and used within a few weeks, since peptides in solution degrade over time.
Is research-grade Biotinoyl Tripeptide-1 an approved drug?
No. Biotinoyl Tripeptide-1 is a cosmetic-grade ingredient for topical formulation and research, not an approved medicine; the evidence supports only modest topical, cosmetic effects. Everything here is research and educational information, not medical advice.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.